<DOC>
	<DOCNO>NCT01248338</DOCNO>
	<brief_summary>An impairment endothelial function play central role pathogenesis cardiovascular disease complication . Most cardiovascular risk factor know impair endothelial function establish disease aggravate endothelial dysfunction . The aim present study investigate effect nebivolol metoprolol succinate endothelial function large artery stiffness .</brief_summary>
	<brief_title>Effects Nebivolol Versus Metoprolol Succinate Endothelial Function</brief_title>
	<detailed_description>The aim study compare effect vasodilating β-blocker nebivolol cardioselective β-blocker metoprolol succinate aortic blood pressure leave ventricular wall thickness . We conduct randomize , double-blind study 80 hypertensive patient . Patients receive either nebivolol 5 mg metoprolol succinate 50-100 mg daily one year . Their heart rate , central brachial blood pressure , mean arterial pressure , augmentation index , carotid-femoral pulse wave velocity leave ventricular wall thickness measure baseline end study .</detailed_description>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Patients mild moderate essential hypertension ( systolic BP 140179 mmHg and/or diastolic BP 90109 mmHg ) * Male female patient age 3065 year Newly diagnose untreated patient previously diagnose patient without treatment least two week prior screening* If patient take previously antihypertensive medication BP value originate untreated two week randomization Concomitant medication : Cyclic antidepressant , MAO inhibitor , corticosteroid Diabetes I II type ( fast venous plasma glucose &gt; 6.4 mmol/l ) Bronchial asthma chronic obstructive airway disease Body mass index &gt; 30 kg/m2 Ischaemic heart disease ( III , IV stage , Canadian Cardiovascular Society ) Clinically relevant heart failure ( NYHA class II IV ) Clinically relevant valve disease ( physical examination ) Arrhythmias conduction disturbance , require therapy , sinus bradycardia rest &lt; 50 b/min , sick sinus syndrome , AV block stage II III Secondary hypertension ( urea &gt; 8.3 mmol/l , creatinine &gt; 120μmol/l ( male ) , &gt; 103 μmol/l ( female ) , TSH &gt; 4.0mIU/l , free T4 &gt; 27 pmol/l ) Clinically relevant atherosclerotic disease low extremity Acute inflammation ( accord CRP &gt; 10mg/l ) Hypercholesterolemia ( &gt; 6,5 mmol/l ) Allergic reaction betablockers Pregnant breastfeed woman History hepatic , renal , metabolic endocrine disease Smoking &gt; 10 cigarette per day Alcohol consumption &gt; 7 drink per week ( drink = 0,33 l beer , 120 ml wine 30 ml strong alcoholic drink ) The patient surgery disease gastrointestinal tract , opinion investigator , may influence absorption elimination study drug . The patient severe organic disorder may interfere absorption , pharmacokinetics , elimination study medication . The patient comorbid condition would expect result death trial period ( e.g. , terminal cancer , AIDS ) . The patient chronic psychoses behavioural condition would limit ability patient comply requirement study . The patient know hypersensitivity Nebivolol , Metoprolol hydrochlorothiazide relate compound . Patient enrol another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>